To date, PARP-1 inhibitors have been approved for the treatment of several types of cancer patients [8], and PARP inhibitors might be an innovative approach to the treatment of inflammatory disorders [9–11] and neurodegenerative diseases [12, 13]. This evidence concerns the gene PARP1 and neurodegenerative disease.